What is Lifesci Capital’s Forecast for CNTA Q3 Earnings?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Investment analysts at Lifesci Capital issued their Q3 2025 earnings per share estimates for Centessa Pharmaceuticals in a research note issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($0.38) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals’ Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03).

Several other equities analysts have also commented on CNTA. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a “buy” rating and a $35.00 target price for the company. Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an “outperform” rating and a $40.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Truist Financial began coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Finally, Wall Street Zen downgraded Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.45.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $15.73 on Friday. The firm has a market capitalization of $2.11 billion, a P/E ratio of -8.79 and a beta of 1.47. The stock has a fifty day moving average price of $15.99 and a 200 day moving average price of $14.46. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $19.09. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after buying an additional 870 shares during the last quarter. HighMark Wealth Management LLC lifted its holdings in Centessa Pharmaceuticals by 0.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock worth $3,118,000 after buying an additional 1,500 shares during the last quarter. HighVista Strategies LLC lifted its holdings in Centessa Pharmaceuticals by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock worth $535,000 after buying an additional 1,664 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. Finally, Trexquant Investment LP lifted its holdings in Centessa Pharmaceuticals by 1.1% during the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock worth $3,796,000 after buying an additional 2,810 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $17.23, for a total value of $103,380.00. Following the completion of the sale, the general counsel owned 105,386 shares of the company’s stock, valued at $1,815,800.78. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the sale, the chief executive officer directly owned 221,017 shares of the company’s stock, valued at $3,518,590.64. The trade was a 19.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold 171,322 shares of company stock worth $2,472,814 over the last three months. 7.09% of the stock is currently owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.